Heart attack patients given more antithrombotic drugs have increased risk of hospital admission for bleeding

December 10, 2009

In heart attack patients, risk of hospital admission for bleeding increases with the number of antithrombotic (clot-busting) drugs used. Patients with non-fatal bleeding are also much more likely to suffer repeat heart attack or die than those without this non-fatal bleeding. This analysis of more than 40,000 Danish patients is reported in an Article in this week's edition of The Lancet, written by Dr Rikke Sørensen, Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, and colleagues.

Combinations of aspirin, clopidogrel, and vitamin K antagonists (such as warfarin) are widely used in patients after a heart attack. However, data on the safety of combinations are sparse. In this study, the authors examined the risk of hospital admission for bleeding associated with different antithrombotic regimens.

By use of nationwide registers from Denmark, the authors identified 40 812 patients aged 30 years or older who had been admitted to hospital with first-time heart attack between 2000 and 2005. Claimed prescriptions starting at hospital discharge were used to determine the regimen prescribed according to the following groups: monotherapy with aspirin, clopidogrel, or vitamin K antagonist; dual therapy with aspirin plus clopidogrel, aspirin plus vitamin K antagonist, or clopidogrel plus vitamin K antagonist; or triple therapy including all three drugs. Risk of hospital admission for bleeding, recurrent heart attack, and death were then assessed for each group.

During a mean follow-up of around 16 months, 1891 (4•6%) patients were admitted to hospital with bleeding or were diagnosed with a bleeding as the cause of death. The yearly incidence of bleeding was 2•6% for the aspirin group, 4•6% for clopidogrel, 4•3% for vitamin K antagonist, 3•7% for aspirin plus clopidogrel, 5•1% for aspirin plus vitamin K antagonist, 12•3% for clopidogrel plus vitamin K antagonist, and 12•0% for triple therapy.

With aspirin as reference (1.0), increased risk of bleeding was 1•3 for clopidogrel, 1•2 for vitamin K antagonist*, 1•5 for aspirin plus clopidogrel, 1•8 for aspirin plus vitamin K antagonist, 3•5 for clopidogrel plus vitamin K antagonist, and 4•1 for triple therapy.

The number of patients that needed to be treated in one year in order for one to be harmed, (the number needed to harm) was 81 for aspirin plus clopidogrel, 45 for aspirin plus vitamin K antagonist, 15 for clopidogrel plus vitamin K antagonist, and 13 for triple therapy. 702 (38%) of 1852 patients with non-fatal bleeding had recurrent heart attack or died during the study period compared with 7178 (18%) of 38 960 patients without non-fatal bleeding.

The authors conclude: "In patients with first-time heart attack, all combinations of aspirin, clopidogrel, and vitamin K antagonists are associated with increased risk of nonfatal and fatal bleeding, apart from monotherapy with a vitamin K antagonist, compared with aspirin alone. Increased risk of bleeding was proportional to the number of drugs used. Non-fatal bleeding is an independent predictor associated with increased risk of recurrent heart attack or death. We propose that treatment with triple therapy or dual therapy with clopidogrel plus vitamin K antagonist should be prescribed only after thorough individual risk assessment and careful consideration of the risk-benefit ratio."

In an accompanying Comment, Dr Erik L Grove, Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, and Dr Robert F Storey, Department of Cardiovascular Science, University of Sheffield, UK, say: "The findings by Sørensen and colleagues suggest that a greater awareness of the prognostic importance of bleeding is warranted; they also underline the need for careful selection of antithrombotic drug combinations according to individual patient's characteristics."
-end-
Dr Rikke Sørensen, Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark.T) +45 23962884 E) rs@heart.dk

Dr Erik L Grove, Department of Cardiology, Aarhus University Hospital, Skejby, Denmark. T) +45 6178 9091 E) erikgrove@dadlnet.dk

For full Article and Comment, see: http://press.thelancet.com/riskbleeding.pdf

Note to editors: *This particular finding (for vitamin K antagonists) was not statistically significant.

Lancet

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.